hrs4r
 I want to donate
Firma
ARANTXA ERASO-URIÉN
Position
Cap de Grup - R4
Group leader - R4

Projectes

Codi oficial: Estudio PREV Start date:01/11/2021 Data fi: 31/12/2025 Investigador/a principal: ARANTXA ERASO URIÉN, SERGI MORAL TORRES Organisme finançador: FUNDACION MERCK SALUD
Codi oficial: ADARNAT I Start date:09/12/2022 Data fi: 09/12/2027 Investigador/a principal: LUIS MIGUEL ALONSO RUANO, ARANTXA ERASO URIÉN Organisme finançador: ASSOCIACIÓ ESPANYOLA CONTRA EL CÀNCER
Codi oficial: 2021 SGR 01463 - ONCORFIM Girona Start date:01/01/2022 Data fi: 30/06/2025 Investigador/a principal: ARANTXA ERASO URIÉN Organisme finançador: AGÈNCIA DE GESTIÓ UNIVERSITARIS I RECERCA (AGAUR)
Codi oficial: 101162826 Start date:01/05/2024 Data fi: 31/10/2025 Investigador/a principal: ARANTXA ERASO URIÉN Organisme finançador: EUROPEAN COMISSION

Publicacions

Marruecos Querol J, Jurado-Bruggeman D, Lopez-Vidal A, Mesía Nin R, Rubió-Casadevall J, Buxó M, Eraso Urien A

Contouring aid tools in radiotherapy. Smoothing: the false friend.

CLINICAL & TRANSLATIONAL ONCOLOGY, 2024 dx.doi.org/10.1007/s12094-024-03420-9
Zamora, V, Garin, O, Suárez, JF, Gutiérrez, C, Guedea, F, Cabrera, P, Castells, M, Herruzo, I, Fumadó, L, Samper, P, Ferrer, C, Regis, L, Pont, A, Ferrer, M

Comparative effectiveness of new treatment modalities for localized prostate cancer through patient-reported outcome measures

Clinical and Translational Radiation Oncology, 2024, 44 dx.doi.org/10.1016/j.ctro.2023.100694
Marruecos-Querol J, Rubió-Casadevall J, Lozano A, Buxó M, Puigdemont M, Linares I, Planas I, Vayreda J, Cirauqui B, Taberna M, Quiroga V, Tobed M, Borés A, Recalde S, Saigi M, Felip E, Eraso A, Mesía R

Validation of a prognostic model for predicting larynx preservation outcome (TALK score) in a Southern European population.

CLINICAL & TRANSLATIONAL ONCOLOGY, 2023, 25, 2384-2392 dx.doi.org/10.1007/s12094-023-03121-9
Auñón C, Sanvisens A, Turon E, Vidal-Vila A, Puigdemont M, Osca-Gelis G, Eraso A, Marcos-Gragera R

Time trends and survival of marginal zone lymphoma over 25 years in Girona, Spain (1994-2018).

CANCER MEDICINE, 2023, 12, 12343-12353 dx.doi.org/10.1002/cam4.5935
Pardo García R, Piñero Madrona A, Algara López M, Bernet Vegué L, Eraso Urien A

Just medical oncology guidelines….

CLINICAL & TRANSLATIONAL ONCOLOGY, 2023, 25, 3319-3320 dx.doi.org/10.1007/s12094-023-03272-9
Coma N, Resta H, Moral S, Eraso MA, Ventura M, Brugada R

Uncommon short- and long-term cardiological side effects of thoracic radiation: a report of two cases.

Future Cardiology, 2023, 19, 529-535 dx.doi.org/10.2217/fca-2023-0027
Sanz J, Eraso A, Ibáñez R, Williams R, Algara M

Tumor Bed Boost Radiotherapy in the Conservative Treatment of Breast Cancer: A Review of Intra-Operative Techniques and Outcomes.

Cancers, 2023, 15 dx.doi.org/10.3390/cancers15164025
Coma, N, Moral, S, Ballesteros, E, Eraso, A, Ventura, M, Pujol, E, Brugada, R

Current Evidence on the Benefit of Exercise in Cancer Patients: Effects on Cardiovascular Mortality, Cardiotoxicity, and Quality of Life

REVIEWS IN CARDIOVASCULAR MEDICINE, 2023, 24 dx.doi.org/10.31083/j.rcm2406160
Eraso, A, Ciervide, R, Ibañez, R

Can the patient with oligometastatic breast cancer be rescued with radiation therapy?

Revista de Senologia y Patologia Mamaria, 2023, 36 dx.doi.org/10.1016/j.senol.2023.100501
Sanz-Latiesas, J, Ibáñez-Carreras, R, Eraso-Urién, A, Algara-López, M

Can intraoperative radiation therapy be performed in early-stage breast cancer treatment as standard care?

Revista de Senologia y Patologia Mamaria, 2023, 36 dx.doi.org/10.1016/j.senol.2023.100500

Formulari de contacte

About IDIBGI!

menu